Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2014

Open Access 01-12-2014 | Research

Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues

Authors: Linjiang Pan, Suning Huang, Rongquan He, Minhua Rong, Yiwu Dang, Gang Chen

Published in: European Journal of Medical Research | Issue 1/2014

Login to get access

Abstract

Background

Aberrant expression of microRNA-148a (miR-148a) has been reported in several types of malignancies. However, its expression and clinicopathological significance in hepatocellular carcinoma (HCC) has not been entirely clarified. Our objective was to investigate the clinicopathological contribution of the miR-148a expression in HCC formalin-fixed paraffin-embedded (FFPE) tissues.

Methods

Eighty-nine HCC and their para-cancerous liver tissues were recruited. Total mRNA including miRNA was isolated and miR-148a expression was determined by using real time RT-qPCR. Furthermore, the relationship between the miR-148a level and clinicopathological features was explored.

Results

Significantly lower miR-148a expression in HCC tissues was observed than that in adjacent noncancerous hepatic tissues. miR-148a expression was also correlated to clinical TNM stage, metastasis, status of capsular infiltration and numbers of tumor nodes.

Conclusions

Underexpression of miR-148a might be associated with HCC tumorigenesis and deterioration of HCC. miR-148a might act as a suppressor miRNA of HCC and it therefore has a potential role in prognosis of HCC patients.
Appendix
Available only for authorised users
Literature
1.
Liu B, Mao A, Liu D: The hypothesis of an effective strategy for resistance of hepatocellular carcinoma to therapy-autophagy. West Indian Med J 2011, 60(6):666–668.PubMed
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69–90. 10.3322/caac.20107PubMedCrossRef
3.
Vertemati M, Moscheni C, Petrella D, Lamperti L, Cossa M, Gambacorta M, Goffredi M, Vizzotto L: Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis. Pathol Res Pract 2012, 208(4):240–244. 10.1016/j.prp.2012.02.007PubMedCrossRef
4.
Abdo AA, Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, Al-Hamoudi W, Ali SM, Al-Ashgar HI, Al-Mdani A, Albenmousa A, Al Faleh FZ, Al-Anazi M, Khalaf N, Al-Qahtani A: IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int 2013, 7(2):533–538. 10.1007/s12072-013-9421-8PubMedPubMedCentralCrossRef
5.
Park CW, Cho MC, Hwang K, Ko SY, Oh HB, Lee HC: Comparison of quasispecies diversity of HCV between chronic hepatitis C and hepatocellular carcinoma by ultradeep pyrosequencing. BioMed Res Int 2014, 2014: 853076.PubMedPubMedCentral
6.
Liu F, You X, Chi X, Wang T, Ye L, Niu J, Zhang X: Hepatitis B virus X protein mutant HBxDelta127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT. Biochem Biophys Res Commun 2014, 444(2):128–134. 10.1016/j.bbrc.2014.01.004PubMedCrossRef
7.
Kretzer IF, Do Livramento A, Da Cunha J, Goncalves S, Tosin I, Spada C, Treitinger A: Hepatitis C worldwide and in Brazil: silent epidemic-data on disease including incidence, transmission, prevention, and treatment. Sci World J 2014, 2014: 827849. 10.1155/2014/827849CrossRef
8.
Hu L, Chen G, Yu H, Qiu X: Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 2010, 4(1):423–432. 10.1007/s12072-010-9164-8PubMedPubMedCentralCrossRef
9.
Chen G, Luo D: Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 2008, 21(6):275–278.PubMed
10.
Chen G, Dang YW, Luo DZ, Feng ZB, Tang XL: Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res 2008, 17(4):183–189. 10.3727/096504008785114138PubMedCrossRef
11.
Chen G, Luo DZ, Liu L, Feng ZB, Guo F, Li P: Hepatic local micro-environmental immune status in hepatocellular carcinoma and cirrhotic tissues. West Indian Med J 2006, 55(6):403–408. 10.1590/S0043-31442006000600007PubMedCrossRef
12.
Chen G, Luo D: Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci 2008, 113(3):297–304. 10.3109/2000-1967-240PubMedCrossRef
13.
Yang M, Chen G, Dang Y, Luo D: Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci 2010, 115(4):232–237. 10.3109/03009734.2010.516410PubMedPubMedCentralCrossRef
14.
Ruan ZP, Xu R, Lv Y, Tian T, Wang WJ, Guo H, Nan KJ: PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncol Res 2012, 20(2–3):113–121. 10.3727/096504012X13477145152995PubMedCrossRef
15.
Zhuang L, Wu Y, Han J, Ling X, Wang L, Zhu C, Fu Y: A network biology approach to discover the molecular biomarker associated with hepatocellular carcinoma. BioMed Res Int 2014, 2014: 278956. 10.1155/2014/278956PubMedPubMedCentralCrossRef
16.
Sen R, Ghosal S, Das S, Balti S, Chakrabarti J: Competing endogenous RNA: the key to posttranscriptional regulation. Sci World J 2014, 2014: 896206. 10.1155/2014/896206CrossRef
17.
Omelia EJ, Uchimoto ML, Williams G: Quantitative PCR analysis of blood- and saliva-specific microRNA markers following solid-phase DNA extraction. Anal Biochem 2013, 435(2):120–122. 10.1016/j.ab.2012.12.024PubMedCrossRef
18.
Hui A, How C, Ito E, Liu FF: Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer 2011, 11: 500. 10.1186/1471-2407-11-500PubMedPubMedCentralCrossRef
19.
Di Leva G, Briskin D, Croce CM: MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci 2012, 117(2):202–216. 10.3109/03009734.2012.660551PubMedPubMedCentralCrossRef
20.
Siegrist F, Singer T, Certa U: MicroRNA expression profiling by bead array technology in human tumor cell lines treated with interferon-alpha-2a. Biol Proced Online 2009, 11: 113–129. 10.1007/s12575-009-9012-1PubMedPubMedCentralCrossRef
21.
22.
Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K: MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011, 6(1):e16435. 10.1371/journal.pone.0016435PubMedPubMedCentralCrossRef
23.
Hung CH, Chiu YC, Chen CH, Hu TH: MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. BioMed Res Int 2014, 2014: 486407.PubMedPubMedCentral
24.
Zhang JP, Zeng C, Xu L, Gong J, Fang JH, Zhuang SM: MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 2014, 33(31):4069–4076. 10.1038/onc.2013.369PubMedCrossRef
25.
Gailhouste L, Gomez-Santos L, Hagiwara K, Hatada I, Kitagawa N, Kawaharada K, Thirion M, Kosaka N, Takahashi RU, Shibata T, Miyajima A, Ochiya T: miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology 2013, 58(3):1153–1165. 10.1002/hep.26422PubMedCrossRef
26.
Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C, De Greve J: miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 2013, 8(3):e60317. 10.1371/journal.pone.0060317PubMedPubMedCentralCrossRef
27.
Dang Y, Luo D, Rong M, Chen G: Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One 2013, 8(4):e61054. 10.1371/journal.pone.0061054PubMedPubMedCentralCrossRef
28.
Rong M, Chen G, Dang Y: Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro . BMC Cancer 2013, 13: 21. 10.1186/1471-2407-13-21PubMedPubMedCentralCrossRef
29.
Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med 2012, 10: 28. 10.1186/1741-7015-10-28PubMedPubMedCentralCrossRef
30.
Ramshankar V, Krishnamurthy A: Lung cancer detection by screening - presenting circulating miRNAs as a promising next generation biomarker breakthrough. Asian Pac J Cancer Prev 2013, 14(4):2167–2172. 10.7314/APJCP.2013.14.4.2167PubMedCrossRef
31.
Qu H, Xu W, Huang Y, Yang S: Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev 2011, 12(5):1117–1125.PubMed
32.
Tsai HL, Yang IP, Huang CW, Ma CJ, Kuo CH, Lu CY, Juo SH, Wang JY: Clinical significance of microRNA-148a in patients with early relapse of stage II stage and III colorectal cancer after curative resection. Transl Res 2013, 162(4):258–268. 10.1016/j.trsl.2013.07.009PubMedCrossRef
33.
Kodahl AR, Zeuthen P, Binder H, Knoop AS, Ditzel HJ: Alterations in circulating miRNA Levels following early-stage estrogen receptor-positive breast cancer resection in post-menopausal women. PLoS One 2014, 9(7):e101950. 10.1371/journal.pone.0101950PubMedPubMedCentralCrossRef
34.
Kim SY, Jeon TY, Choi CI, Kim DH, Kim DH, Kim GH, Ryu DY, Lee BE, Kim HH: Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagn 2013, 15(5):661–669. 10.1016/j.jmoldx.2013.04.004PubMedCrossRef
35.
Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ: Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol 2012, 29(4):2402–2408. 10.1007/s12032-012-0210-3PubMedCrossRef
36.
Yan H, Dong X, Zhong X, Ye J, Zhou Y, Yang X, Shen J, Zhang J: Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog 2014, 53(12):960–969.PubMed
37.
Long XR, He Y, Huang C, Li J: MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J Oncol 2014, 44(6):1915–1922.PubMed
Metadata
Title
Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues
Authors
Linjiang Pan
Suning Huang
Rongquan He
Minhua Rong
Yiwu Dang
Gang Chen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2014
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-014-0068-2

Other articles of this Issue 1/2014

European Journal of Medical Research 1/2014 Go to the issue

Research

Expressions of heparanase and upstream stimulatory factor in hepatocellular carcinoma

Research

Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group

Research

Dynamic change of glomerular filtration rate in the early stage is associated with kidney allograft status: a preliminary report

Research

Construction of microRNA and transcription factor regulatory network based on gene expression data in cardiomyopathy

Research article

Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma

Research

Analysis of foot and ankle disorders and prediction of gait in multiple sclerosis rehabilitation